Keyphrases
Antiphospholipid Syndrome
100%
Oral Administration
100%
Immunological Tolerance
100%
Oral Tolerance
28%
Humoral Immunity
14%
Inflammatory Response
14%
Inflammatory Cytokines
14%
Mouse Model
14%
Interleukin-10
14%
New Therapeutic Approaches
14%
Quantitative PCR
14%
Interleukin-6
14%
Autoantibodies
14%
Anti-inflammatory Response
14%
Balb C Mice
14%
Anti-inflammatory Cytokines
14%
Orally Administered
14%
Disease Pathogenesis
14%
Immunomodulation
14%
Novel Therapies
14%
Decreased Expression
14%
Interleukin-17 (IL-17)
14%
Intolerance
14%
Splenocytes
14%
Thrombus
14%
Immune Signaling
14%
Fetal Loss
14%
Tolerogenic Dendritic Cells
14%
Tolerance Induction
14%
I-domain
14%
Circulating microRNA
14%
Immunology and Microbiology
Antiphospholipid Syndrome
100%
Immune Tolerance
100%
Inflammation Response
28%
Inflammatory Cytokine
28%
Humoral Immunity
14%
Mouse Model
14%
Reverse Transcription Polymerase Chain Reaction
14%
Interleukin 10
14%
Autoantibodies
14%
Bagg Albino Mouse
14%
Immunomodulation
14%
Dendritic Cell
14%
Interleukin 6
14%
Immunity
14%
Splenocyte
14%
Interleukin 17
14%